Corbus Pharmaceuticals Stock (NASDAQ:CRBP)

Forecast Financials Chart

Previous Close

$4.13

52W Range

$3.93 - $18.11

50D Avg

$7.77

200D Avg

$8.72

Market Cap

$78.33M

Avg Vol (3M)

$855.37K

Beta

2.63

Div Yield

CRBP Company Profile

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Oct 27, 2014

Website

CRBP Performance

CRBP Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	-	$-48.72M	$-45.08M
Net Income	$-78.54M	$-40.21M	$-44.60M
EBITDA	-	$-37.74M	$-40.10M
Basic EPS	$-5.90	$-3.68	$-10.31
Diluted EPS	$-5.90	$-3.68	$-10.31

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 20Mar 15, 21 | 8:30 AM

Q3 20Nov 10, 20 | 8:30 AM

Q2 20Aug 06, 20 | 8:30 AM

Peer Comparison

Ticker	Company
ELTX	Elicio Therapeutics, Inc.
RANI	Rani Therapeutics Holdings, Inc.
IPHA	Innate Pharma S.A.
MIST	Milestone Pharmaceuticals Inc.
ALEC	Alector, Inc.
CRDF	Cardiff Oncology, Inc.
PEPG	PepGen Inc.
MOLN	Molecular Partners AG